Has Amgen
We'd submit another bit of evidence: Amgen CEO Kevin Sharer has found his pay package in the spotlight. A recent special report by The Washington Post used Sharer as its prime example of a CEO with a whopping compensation plan at a time when regular workers' wages are stagnating -- and his own company's stock isn't performing up to par.
Big Pharma's top executives are familiar with those sorts of questions. Just consider Johnson & Johnson's Bill Weldon, Abbott Laboratories' Miles White, Schering-Plough's ex-chief Fred Hassan, even the comparatively lower-paid Novartis chairman and ex-CEO Daniel Vasella, whose compensation ranked him as the highest-paid company chief in Switzerland. They've seen their names and dollar signs in headlines plenty of times.
And then there's the less-attractive fact that Amgen is negotiating a marketing settlement with the U.S. Justice Department. The company recently announced that it was setting aside $780 million for a potential resolution to long-running allegations that it improperly promoted its anemia drugs Epogen and Aranesp. That figure puts it right in the middle of Big Pharma peers AstraZeneca
This article originally published here. Get your free daily pharma briefing here.
Related Articles: